Applied Filters
Carpmaels & Ransford name two new partners
Carpmaels & Ransford has appointed two life sciences attorneys as partners, effective yesterday, July 1.
SPC generics waiver comes into force
The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.
AbbVie to acquire Allergan for $63bn
US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.
English High Court refuses to grant Pfizer Arrow declaration
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
GSK unites with CRISPR pioneer Doudna
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
EU General Court rejects lactic acid supplement TM
The EU’s General Court has upheld the European Union Intellectual Property Office’s finding that a trademark for dietary supplements was descriptive of the relevant services to an Italian speaking public.
Sensorion in gene therapy collaboration with Institut Pasteur
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
CMA accuses 4 pharma companies of anti-competitive conduct
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
E+F patent attorney elevated to partner
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
Novartis to boost eye care portfolio with $3.4bn buy
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
